...
机译:美国食品和药物管理局批准:蠕动in用于治疗先进或转移性非小细胞肺癌,这是一个促进淋巴瘤激酶阳性
Clinical Investigations Branch Cancer Therapy Evaluation Program National Cancer Institute;
Offices of Hematology and Oncology Products Center for Drug Evaluation and Research Food and Drug;
Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiologic Health U;
Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiologic Health U;
Offices of Biostatistics Center for Drug Evaluation and Research U.S. Food and Drug;
Offices of Biostatistics Center for Drug Evaluation and Research U.S. Food and Drug;
Offices of Clinical Pharmacology Center for Drug Evaluation and Research U.S. Food and Drug;
Offices of Clinical Pharmacology Center for Drug Evaluation and Research U.S. Food and Drug;
Offices of Clinical Pharmacology Center for Drug Evaluation and Research U.S. Food and Drug;
Offices of Hematology and Oncology Products Center for Drug Evaluation and Research Food and Drug;
Offices of Hematology and Oncology Products Center for Drug Evaluation and Research Food and Drug;
Offices of Hematology and Oncology Products Center for Drug Evaluation and Research Food and Drug;
Offices of Hematology and Oncology Products Center for Drug Evaluation and Research Food and Drug;
Offices of Hematology and Oncology Products Center for Drug Evaluation and Research Food and Drug;
机译:美国食品和药物管理局批准:蠕动in用于治疗先进或转移性非小细胞肺癌,这是一个促进淋巴瘤激酶阳性
机译:FDA批准摘要:克唑替尼用于治疗间变性淋巴瘤激酶重排的转移性非小细胞肺癌
机译:第一线Ceritinib和Crizotinib在先进或转移性促进淋巴瘤激酶阳性非小细胞肺癌中的比较疗效:与外部对照的调整后间接比较
机译:在非小肺癌细胞中的谱分析EGFR激酶抑制剂抵抗途径
机译:了解JunB转录因子在间变性淋巴瘤激酶阳性,间变性大细胞淋巴瘤中的功能。
机译:在美国食品和药物管理局批准克唑替尼后的几周内治疗间变性淋巴瘤激酶阳性的肺癌
机译:在局部晚期或转移性内抑制淋巴瘤激酶阳性非小细胞肺癌中是否有一个益处或二线屈曲inib?元分析